Elvire Pons‐Tostivint

Trastuzumab Deruxtecan in Patients With <i>HER2</i>-Mutant Metastatic Non–Small-Cell Lung Cancer: Primary Results From the Randomized, Phase II DESTINY-Lung02 Trial

Kōichi Goto, Yasushi Goto, Toshio Kubo et al. · Journal of Clinical Oncology · 2023 · 299 citations · Full text

Medicine, Oncology, Pharmacology +17

Response to salvage chemotherapy after progression on immune checkpoint inhibitors in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck

Khalil Saleh, Amaury Daste, Nicolas Martin et al. · European Journal of Cancer · 2019 · 183 citations

Medicine, Oncology, Chemotherapy +10

Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study

Myung‐Ju Ahn, Kentaro Tanaka, Luis Paz‐Ares et al. · Journal of Clinical Oncology · 2024 · 182 citations · Full text

Medicine, Oncology, Pharmacology +9

Efficacy and safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive breast cancer with brain metastases

William Jacot, Elvire Pons‐Tostivint, Jean‐Sébastien Frenel et al. · Breast Cancer Research and Treatment · 2016 · 118 citations

Medicine, Oncology, Breast Oncology +10

Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial

Benjamin Besse, Elvire Pons‐Tostivint, Keunchil Park et al. · Nature Medicine · 2024 · 116 citations · Full text

Medicine, Oncology, Pharmacology +17